Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
8.07
-0.07 (-0.86%)
At close: Jun 5, 2026, 4:00 PM EDT
8.12
+0.05 (0.62%)
After-hours: Jun 5, 2026, 4:10 PM EDT
Instil Bio Employees
Instil Bio had 17 employees as of December 31, 2025. The number of employees increased by 3 or 21.43% compared to the previous year.
Employees
17
Change (1Y)
3
Growth (1Y)
21.43%
Revenue / Employee
n/a
Profits / Employee
-$2,786,824
Market Cap
54.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 14 | -35 | -71.43% |
| Dec 31, 2023 | 49 | -143 | -74.48% |
| Dec 31, 2022 | 192 | -220 | -53.40% |
| Jun 30, 2022 | 463 | 156 | 50.81% |
| Mar 31, 2022 | 437 | 195 | 80.58% |
| Dec 31, 2021 | 412 | 262 | 174.67% |
| Sep 30, 2021 | 382 | 232 | 154.67% |
| Jun 30, 2021 | 307 | - | - |
| Mar 31, 2021 | 242 | - | - |
| Dec 31, 2020 | 150 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 119 |
| Xilio Therapeutics | 76 |
| aTyr Pharma | 60 |
| Mereo BioPharma Group | 39 |
| Entera Bio | 22 |
| Edesa Biotech | 17 |
| Hyperion DeFi | 9 |
| Dogwood Therapeutics | 8 |
TIL News
- 23 days ago - Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Instil Bio downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 5 months ago - Baird downgrades Instil Bio on discontinuation of AXN-2510 - TheFly
- 5 months ago - Instil Bio downgraded to Neutral from Outperform at Baird - TheFly
- 5 months ago - Instil Bio’s Axion discontinues clinical development of AXN-2510 - TheFly
- 5 months ago - Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco - GlobeNewsWire
- 7 months ago - Instil Bio reports Q3 EPS ($1.75) vs ($2.55) last year - TheFly